Evogliptin is a novel, potent and selective
dipeptidyl peptidase 4 inhibitor that has received approval for use in the treatment of
type 2 diabetes in South Korea. In the management of diabetes, it is important to reduce cardiovascular risk factors, as this can decrease the complication and mortality rate. However, the effect of
evogliptin on the atherosclerotic progression has not been evaluated. In this study, we examined the effects of
evogliptin on the progression of
atherosclerosis and its possible mechanism of action. The anti-atherosclerotic effect of
evogliptin was evaluated in ApoE-knockout mice fed high-fat diet analysed by plaque lesion formation,
lipid profiles and vascular inflammatory response in the atherosclerotic progression. The in vitro effects of
evogliptin were verified in endothelial cells analysed by immunoblotting,
siRNA gene knockdown, promoter-
luciferase assay, immunoprecipitation and adhesion assay.
Evogliptin reduced the high-fat diet-induced
atherosclerotic plaque area in the
ApoE-/- mouse model. Macrophage infiltration into lesions was suppressed in the
evogliptin group. In the endothelial cells,
evogliptin inhibited inflammatory responses via suppression of adhesion molecules induced by TNF-α. TNF-α-mediated activation of NF-κB was ameliorated by
evogliptin via the interaction of NF-κB with
SIRT1 (Sirtuin-1). TNF-α-mediated adhesion between endothelial cells and monocytes was inhibited by
evogliptin, but this inhibitory effect was reversed by
Sirt1 gene knockdown. This study demonstrates that the protective effect of
evogliptin on atherosclerotic progression via inhibition of vascular
inflammation. The findings imply that
evogliptin has potential for anti-
atherosclerosis therapy that targets
arterial inflammation.